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Pr esen tation of C a se
Dr. Fundisiwe Chonco (Department of Virology, University of KwaZulu-Natal, Durban, 
South Africa): A 19-year-old woman was seen in a clinic at McCord Hospital in 
Durban, KwaZulu-Natal Province, South Africa (which is affiliated with Massachu-
setts General Hospital), because of headache, fatigue, and vaginal discharge.
The patient had been well until approximately 18 days earlier, when she began 
to have a vaginal discharge, followed by headache, fatigue, sore throat, and anorexia. 
On the fifth day of symptoms, she went to an outpatient clinic in an urban area. 
On examination, she had a vaginal discharge; the temperature and the remainder 
of the examination were reportedly normal. Two different rapid screening tests for 
human immunodeficiency virus type 1 (HIV-1) performed on a finger-stick blood 
sample were negative. Doxycycline, metronidazole, and ceftriaxone were adminis-
tered according to South African guidelines for sexually transmitted diseases. The 
patient was invited to participate in a South African clinical research study; she 
accepted, and additional blood specimens were obtained. She was referred to the 
study clinic at McCord Hospital for follow-up, where she was seen 13 days later.
The patient reported persistent headache, fatigue, sore throat, and vaginal dis-
charge. She was nulliparous and had a history of developmental delay after an ac-
cident during childhood; she was otherwise well. She was on no medications and 
had no known allergies. She was born in South Africa, lived with relatives in a 
house in an urban area of KwaZulu-Natal Province, and attended school. She had no 
history of sexually transmitted diseases and reported having had sexual intercourse 
four times with her 25-year-old boyfriend of 6 months, who had been her only part-
ner. He reportedly had refused her request to use condoms.
On examination, the weight was 73 kg, the temperature 36.0°C, the blood 
pressure 93/59 mm Hg, and the pulse 82 beats per minute. There was a white, mal-
odorous vaginal discharge; the remainder of the examination was normal ex-
cept for findings consistent with the patient’s chronic developmental delay. Ad-
ditional blood specimens were obtained, and both these and specimens from the 
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first clinic were sent to a reference laboratory for 
testing.
During the next 14 days, headache, fatigue, 
anorexia, sore throat, and vaginal discharge re-
solved, but a painful genital ulcer developed. The 
patient returned to the McCord Hospital clinic. 
She had no history of oral or genital ulcers and 
had not been sexually active since her visit to the 
first clinic. She was aware of HIV and that it is 
sexually transmitted.
On examination, the vital signs were normal. 
There was a painful pink ulcer, 5 mm by 10 mm, 
on the labia majora on the left side, with under-
mined borders and without surrounding indura-
tion. There were palpable lymph nodes, 1 cm or 
smaller in diameter, in the submental, posterior 
cervical, and epitrochlear regions. The remainder 
of the examination was normal. Penicillin G ben-
zathine and erythromycin were administered ac-
cording to South African guidelines for genital 
ulcers. A rapid plasma reagin test was negative.
Diagnostic test results were reviewed.
Differ en ti a l Di agnosis
Dr. W.D. Francois Venter: This young woman in Kwa-
Zulu-Natal, who is sexually active and not using 
condoms or contraceptives, has a vaginal dis-
charge, followed by vague but relatively severe 
systemic symptoms, a painful genital ulcer, and 
lymphadenopathy. A travel history might add to 
an already long differential diagnosis, as would a 
history of medication use or visits to a traditional 
health worker, which commonly precede a visit 
to a nurse or doctor. Additional clinical details 
on the symptoms associated with the ulcer would 
allow for a more informed guess as to the cause.
The first question a local clinician would ask 
may seem startling to an outsider in view of this 
patient’s relatively young age: Does this 19-year-
old woman already have established HIV-1 infec-
tion? The patient’s geographic and social demo-
graphic profile makes HIV infection a major issue 
to consider. A large study involving South African 
adolescents suggests that 13.8% of 19-year-old 
women tested positive for HIV, and more than 
30% tested positive by the age of 21 years.1 This 
extraordinary risk occurs even in the context of 
few sexual partners, making a more detailed sex-
ual history unlikely to add much to this assess-
ment.2 In addition, this patient has a neurologic 
deficit due to a childhood accident, which is also 
a risk factor for HIV infection.3
Sexually Transmitted Infections
The presence of a genital ulcer means that this 
patient has a high likelihood of HIV infection. In 
some South African provinces, more than 75% of 
patients who have genital ulcers and attend a pri-
mary care clinic are found to be HIV-positive.4 The 
cause of the ulcer may be predicted on the basis 
of local epidemiologic trends.5-7 Chancroid has al-
most disappeared from South Africa in the past 
two decades and syphilis rates have decreased to 
record low levels, whereas herpes has become 
steadily more prevalent and is now the most com-
mon cause of genital ulcers.5 Of patients with 
acute HIV infection, 5 to 15% have genital ulcers 
that are caused by HIV.8 This patient also has a 
vaginal discharge. In one recent study in South Af-
rica, the two most common causes of vaginal dis-
charge were bacterial vaginosis and trichomonia-
sis.9 As with genital ulcers, some studies show that 
women in this region of South Africa who present-
ed with a vaginal discharge had a high risk of test-
ing positive for HIV.1
Since clinical presentations of sexually trans-
mitted infections correlate poorly with specific 
organisms, a syndromic therapeutic approach to 
a genital ulcer and discharge has been widely ac-
cepted and successful in South Africa.10,11 Spe-
cific tests that would help identify the organisms 
responsible for the discharge and ulcer include 
swabs and culture, serologic testing, and even bi-
opsy. In reality, such an approach is rarely used 
in resource-poor countries.
Lymphadenopathy
Could an illness other than a sexually transmitted 
infection comprehensively explain this patient’s 
symptoms? Many illnesses can cause lymphade-
nopathy with systemic features, including other 
infectious diseases, connective-tissue diseases, sar-
coid, neoplasms, and medications. There is an in-
timidating list of common infections in this region 
of South Africa, including hepatitis B, toxoplas-
mosis, schistosomiasis, streptococcus, rubella, 
Epstein–Barr virus, cat scratch disease, typhoid, 
infective endocarditis, bubonic plague, brucella, 
leptospirosis, abscesses, and typhus. Geography 
tends to limit other considerations such as Lyme 
disease, visceral leishmaniasis (kala-azar), try-
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panosomiasis, histoplasmosis, and other fungal 
infections.
Acute HIV Infection
Could this patient have acute HIV infection? This 
diagnosis would fit, since she is at high risk for 
newly acquired HIV infection, her antibody tests 
are negative, and she has a syndrome that is con-
sistent with acute infection. The acute retroviral 
syndrome occurs 2 to 3 weeks after infection, usu-
ally coinciding with the onset of viremia, and is 
accompanied by several nonspecific symptoms, 
including fatigue, pharyngitis, weight loss, myal-
gias, and headache.12,13 An astute clinician could 
rapidly limit the differential diagnosis with the use 
of available tools, including a good history tak-
ing and examination. Ruling out acute HIV infec-
tion should be the first step. Testing for HIV-1 
RNA (viral load), testing for p24 antigen or HIV 
antibodies with the use of enzyme immunoassay 
(EIA), or simply repeating antibody testing over a 
period of a few weeks should establish a diagno-
sis of HIV infection and allow for further man-
agement steps.
Dr . Fr a ncois V en ter’s  Di agnosis
Acute HIV infection with a concurrent ulcerative 
sexually transmitted infection.
Pathol o gic a l Discussion
Dr. Thumbi Ndung’u: The diagnostic test in this case 
was testing for HIV-1 RNA in a specimen of blood. 
Accurate diagnosis of HIV-1 infection forms the 
bedrock of many prevention, care, and clinical 
management strategies, and the World Health Or-
ganization has guidelines for expanded HIV test-
ing globally.14 HIV-1 infection can be confirmed 
by testing of body fluids for the virus or for anti-
HIV antibodies.
The diagnostic hallmarks of acute HIV infec-
tion are a negative test for HIV-1 antibodies on 
EIA, an indeterminate or negative test for HIV-1 
on Western blot analysis, and detection of HIV-1 
RNA in plasma. In the outpatient setting, two 
rapid assays performed in parallel may be used in 
place of a third- or fourth-generation HIV EIA. In 
this case, the SD Bioline and Sensa Tri-Line HIV 
assays were used. Early detection of acute HIV in-
fection is important because patients in the early 
phase are highly infectious, owing to the extreme-
ly high viral loads in body fluids before the de-
velopment of antiviral immune responses.
This patient was tested for HIV-1 infection at 
the first clinic with the use of rapid tests on whole 
blood. Rapid HIV tests are performed in the clinic 
or in a nearby laboratory, and results are usually 
available within 30 minutes. Although the results 
of a positive test must be confirmed with supple-
mental tests, rapid testing allows the clinician to 
screen for the presence of HIV-1 antibodies and 
implement a care plan before the patient leaves 
the clinic. The three methods of rapid testing that 
are commonly used are immunoconcentration, im-
munochromatography, and particle agglutination. 
In general, rapid tests use various HIV-1 antigens, 
typically located in the Gag and Env regions of 
HIV, that are fixed or coated on a test strip. If a 
specimen contains HIV antibodies, the antibod-
ies will bind to the test antigens and trigger the 
detection system to generate a positive result. 
Typically, two different tests using different HIV 
antigens should be performed in parallel to make 
the presumptive diagnosis of HIV-1 infection. In 
this case, two rapid tests were performed on the 
initial specimen that was obtained at the first 
clinic and were negative. The patient was coun-
seled and, after she agreed to participate in a re-
search study (South African study EO36/06, Char-
acterization of the Evolution of Adaptive Immune 
Responses in Acute HIV Clade C Virus Infection), 
blood was drawn and sent to the study labora-
tory for additional HIV testing. Testing for HIV 
antibodies with the use of EIA and HIV-1 West-
ern blot was negative.
The plasma was then screened for acute HIV 
infection with the use of pooled nucleic acid test-
ing. Pooling samples is a cost-effective screening 
strategy for the detection of the presence of HIV-1 
RNA. In our clinic, where the prevalence of HIV 
infection is high, plasma samples from six per-
sons are combined and then subjected to nucleic 
acid testing for the presence of HIV-1 RNA. The 
pool containing the sample from our patient was 
positive for HIV-1 RNA, prompting the individual 
testing of the constituent samples. The specimen 
from this patient revealed the presence of HIV-1 
RNA (viral load, 12,445 copies per milliliter of 
plasma). HIV-1 RNA was not detected in any of 
the other samples included in the pool, confirm-
ing that the positive result was due to HIV-1 from 
this patient.
Our patient had several negative HIV-1 screen-
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ing tests (four rapid tests and one HIV EIA), a 
negative HIV-1 Western blot analysis, and detect-
able HIV RNA from a specimen of blood drawn 
at the time of her visit to the first clinic (Table 
1). This combination of test results is diagnostic 
of acute HIV infection (Fig. 1). Blood was also 
obtained from this patient when she presented 
13 days later to the McCord Hospital study clinic. 
HIV testing was performed on this specimen; 
the HIV EIA was positive, and the supplemental 
HIV-1 Western blot analysis was indeterminate. 
Results of an HIV-1 RNA test revealed more 
than 10 million copies of HIV-1 RNA per milli-
liter of plasma, which suggest that this patient 
was in the process of HIV seroconversion (Fig. 1). 
Two weeks later, the HIV-1 Western blot analysis 
became positive. When this patient presented 
to the McCord Hospital clinic, her initial CD4+ 
T-cell count was 240 cells per cubic millimeter. 
Although this seems low, it is consistent with the 
transient decline in the CD4+ lymphocyte count 
that is characteristic of acute HIV infection13,18 
(Table 1).
Epidemiol o gy a nd Pr e v en tion  
of HI V in Sou th A fr ic a
Dr. Quarraisha Abdool Karim: This 19-year-old wom-
an with four lifetime sexual encounters and a 
25-year-old male partner has acute HIV infection 
and an ulcerative sexually transmitted infection. 
She epitomizes the challenges facing young wom-
en in a country where HIV is endemic. With less 
than 1% of the world’s population, South Africa 
bears a disproportionate burden of global HIV 
infections (10% and 5.5 million people), which 
Table 1. Laboratory Data.*
Variable First Clinic Study Clinic at McCord Hospital
13 Days before 
Presentation  
at Study Clinic
On 
Presentation
at Study Clinic
14 Days 
after 
Presentation
29 Days 
after 
Presentation
2.5 Mo 
after 
Presentation
3.5 Mo 
after 
Presentation
Rapid screening for HIV† Negative
EIA Negative Positive
CD4+ T-cell count (per mm3) 240 357 414 564 443
Antibodies to HIV antigens‡
gp160 − +/− + + +
gp120 − +/− + + +
p65 − − − − +
p55 − − + + +
p51 − − − − +
gp41 − − − − +
p40 − − + + +
p31 − − − +/− +/−
p24 − − + + +
p18 − − +/− +/− +
Interpretation of Western 
blot results
Negative Indeterminate Positive Positive Positive
HIV-1 RNA screening pool 
(6 specimens)
Positive
HIV-1 RNA copies/ml 12,445 >10 million 249,618 200,398 71,876 14,561
* EIA denotes enzyme immunoassay, and HIV human immunodeficiency virus.
† Two parallel rapid HIV tests were performed on whole blood. Additional HIV tests (two parallel rapid tests, EIA, 
Western blot, and HIV-1 RNA testing) were performed as part of an acute HIV infection study on a plasma sample 
 obtained at the first clinic.
‡ Antibodies to HIV antigens were determined with the use of Western blot analyses. A minus sign denotes a negative 
test result, a plus–minus sign an indeterminate result, and a plus sign a positive result.
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are predominantly sexually transmitted. HIV in 
South Africa has evolved rapidly — despite a rela-
tively late introduction to the virus — from a prev-
alence of 0.8% in the early 1990s to 26.5% by 
2002, a percentage that has remained relatively 
stable.19 Although access to antiretroviral therapy 
is increasing, the rates of new infections remain 
higher than 5% per year.20,21
Although it may seem surprising that our pa-
tient, with a total of only four sexual encounters, 
has acute HIV infection, her situation is all too 
common in South Africa. A distinctive character-
istic of HIV epidemics in which heterosexual 
spread is dominant is the difference in infection 
rates with respect to age and sex, with women 
acquiring HIV infection at a much earlier age than 
men.22,23 Girls from 15 through 19 years of age 
have a higher rate of HIV infection, by a factor of 
3 to 6, than their male counterparts, even though 
first sexual contact occurs at similar ages; nearly 
peak HIV prevalence in women is reached by the 
age of 20 years.1,3 HIV infection is less common 
in men before the age of approximately 25 years, 
the age of this patient’s partner. The difference 
in sexual coupling patterns, in terms of age and 
sex, and the high prevalence of HIV, continue to 
drive the southern African epidemic.24 In the ru-
ral Vulindlela subdistrict of KwaZulu-Natal, the 
prevalence of HIV infection in pregnant women 19 
to 20 years of age, the age of our patient, is 33%.25
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Figure 1. Laboratory Markers of Acute and Early HIV Infection.
The eclipse period refers to the time after infection when HIV-1 RNA, antigens, and antibodies are undetectable. Acute infection refers 
to the period when HIV-1 RNA or antigens can be detected but antibodies cannot. This is also referred to as the seroconversion window. 
In most cases, detectable antibodies are produced within 30 days after infection, signifying the end of the seroconversion window, but in 
some cases, the window is longer. In the period of recent infection, HIV RNA and antibodies can usually be detected. A combination of 
sensitive and less-sensitive enzyme immunoassays can be used to differentiate between recent and long-standing infections.15 Adapted 
from Rosenberg et al.16 and Branson.17
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Transmission
Although sexual transmission is regarded as the 
least efficient mode of HIV transmission, this pa-
tient illustrates a feature of the South African epi-
demic: paradoxically high rates of HIV transmis-
sion in young women with low coital frequency. 
Although we do not have information about the 
patient’s partner, the higher the partner’s viral 
load, the greater the probability of male-to-female 
and female-to-male HIV transmission.26 During 
the asymptomatic period of infection, the viral 
load is lowest and the risk of transmission is low-
est. However, in the presence of sexually trans-
mitted infections, the viral load during the asymp-
tomatic period can reach elevated levels similar 
to those seen during acute symptomatic HIV in-
fection, and the risk of HIV transmission is ele-
vated, especially if a genital ulcer is present. This 
patient and possibly her partner had an ulcerative 
sexually transmitted infection that probably fa-
cilitated transmission of the virus.
Preventing HIV infection
This case presents us with a key question: What 
can be done to prevent infection with HIV or oth-
er sexually transmitted pathogens? In the three 
decades of the HIV pandemic, substantial advances 
have been made in treating the acquired immu-
nodeficiency syndrome (AIDS) and preventing 
transmission of HIV from infected mothers to 
infants. In contrast, preventing sexual transmis-
sion, which accounts for more than 80% of all 
HIV infections, remains a challenge. A systematic 
review of 37 randomized, controlled trials involv-
ing HIV prevention has revealed that only 5 showed 
successful HIV prevention.27
The so-called ABC approach (abstain, be faith-
ful, and use condoms) remains the foundation of 
HIV prevention. Additional approaches to preven-
tion include male circumcision, as well as coun-
seling and HIV testing to provide knowledge of 
HIV status. Unfortunately for this young woman, 
her partner was unwilling to use a condom. For 
sexually active women who are unable to negoti-
ate monogamy or condom use with their sexual 
partner, there are currently no options for the pre-
vention of HIV. This lack of options underscores 
the urgent need for protective methods that can 
be initiated by women, such as effective micro-
bicides or the prophylactic use of antiretroviral 
drugs for the prevention of infection.28
The Centre for the AIDS Programme of Re-
search in South Africa (CAPRISA) recently an-
nounced the results from the CAPRISA 004 study, 
a phase 2B, randomized, controlled trial of 1% 
tenofovir gel that showed a 39% reduction in HIV 
acquisition in women29 and a 51% reduction in 
the acquisition of herpes simplex virus type 2.25 
Although it is too late for prophylactic therapy for 
our patient, this therapy provides hope that HIV 
prevention methods that can be initiated by wom-
en are within our grasp.
Altering the trajectory of the HIV epidemic 
in southern Africa
What can we do for patients, and how can we in-
tervene to reduce further transmission of HIV? In 
addition to treating the sexually transmitted in-
fections and reducing the viral load for both per-
sonal and public benefit, counseling and support 
to reduce the risk of HIV is critical. Although in-
terventions regarding prevention have consistently 
shown a significant effect,30 these efforts in care 
and treatment programs unfortunately remain 
small or nonexistent.
A critical challenge in altering the trajectory 
of the HIV epidemic in southern Africa is the poor 
recognition of personal risk, as reflected in low 
rates of HIV testing. This patient was aware of 
HIV and its sexual transmission but remained at 
risk for acquiring HIV infection. The South Afri-
can government recently launched a substantive 
campaign to promote knowledge of HIV status 
and a program for medical male circumcision. 
The South African antiretroviral treatment pro-
gram is the largest in the world, but coverage 
remains at about 30% and a lot more needs to 
be done to reach the target of 80%. Clinics for 
the care and treatment of patients with AIDS need 
to expand their services to include counseling re-
garding reducing the risk of HIV, as well as repro-
ductive health services to suppress the transmis-
sion of HIV.
Discussion of M a nagemen t
Dr. Rajesh Gandhi (Medicine): Dr. Venter, could you 
tell us how you would treat this patient?
Dr. Venter: After a diagnosis of acute HIV infec-
tion has been established, management priorities 
should include aggressive retention of patients 
in care programs, treatment and follow-up of the 
vaginal discharge and ulcer, tuberculosis pro-
phylaxis, fertility advice, timely initiation of anti-
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retroviral medication, and appropriate interven-
tions to prevent further transmission.
The genital ulcer and vaginal discharge should 
respond well to therapy according to the new 
South African guidelines, which — mindful of the 
rise in local fluoroquinolone-resistant gonorrhea, 
as well as the increase in herpes as a cause of 
ulcers — now advocate the use of third-genera-
tion cephalosporins in place of ciprofloxacin for 
uncomplicated vaginal discharge (with metroni-
dazole and doxycycline) and acyclovir for the treat-
ment of ulcers (with erythromycin and penicil-
lin).5,12 If the symptoms do not resolve, a more 
focused investigation should be performed after 
it is determined whether the patient adhered to 
her treatment regimen. Treatment of the sexually 
transmitted disease may decrease the plasma viral 
load, which may slow the progression to AIDS.31
Treatment of the patient’s recently acquired HIV 
infection is not so easy. It is clear that a large 
amount of immunologic damage is wrought dur-
ing the first few months after infection.32 How-
ever, antiretroviral treatment of acute HIV infec-
tion is controversial, with no firm evidence of 
clinical benefit, although at least one study sug-
gests immunologic benefit.33 In fact, the timing 
of the initiation of antiretroviral therapy in per-
sons with HIV is still under debate, and we are 
awaiting evidence from randomized, controlled 
trials showing the benefits of treatment at high-
er CD4+ T-cell counts (>350 cells per cubic mil-
limeter).34 Currently, guidelines for most devel-
oped countries advocate treating asymptomatic 
HIV infection in patients who have a CD4+ T-cell 
count below 500 cells per cubic millimeter, with 
many suggesting treatment at higher CD4+ T-cell 
counts.35 World Health Organization guidelines 
take a more conservative approach, suggesting 
treatment at the threshold CD4+ T-cell count of 
350 cells per cubic millimeter for asymptomatic 
patients unless they are pregnant.36 South African 
guidelines recommend treatment for healthy pa-
tients with HIV infection who are not pregnant 
and have a CD4+ count of 200 cells or less per 
cubic millimeter, due to the perceived costs and 
burden on available services.37 Our patient would 
not receive antiretroviral treatment until her CD4+ 
count falls to 200 cells or less per cubic millime-
ter, she becomes pregnant, or an AIDS-defining 
illness develops.
One of the thorniest problems in HIV manage-
ment is keeping patients in a care program when 
they are not provided antiretroviral treatment. The 
retention rate is very poor. In South Africa’s pro-
gram, the average age at the initiation of antiret-
roviral treatment in women is the early 30s, and 
usually the CD4+ count is below 100 cells per cu-
bic millimeter.38 Retaining this teenage woman 
in care is going to be a major challenge. Before 
the patient leaves the clinic, the attending clini-
cian should carefully explain to her the immedi-
ate and long-term care plan and the importance 
of consistent follow-up.
Isoniazid should be started for tuberculosis 
prophylaxis, after active tuberculosis is ruled out 
through basic screening for symptoms, with care-
ful repeat screening for symptoms. South African 
guidelines have removed the need for a purified 
protein derivative skin test. In anticipation of 
her wanting children, she should be given advice 
about fertility and contraception, advised against 
pregnancy while her viral load is likely to be high, 
and encouraged to get informed health care ad-
vice regarding the optimal timing of a pregnancy. 
Any suspicion of pregnancy should be confirmed 
immediately, so that treatment to prevent mother-
to-child transmission can be initiated as soon as 
possible.
Finally, the patient requires intensive counsel-
ing regarding safe-sex practices. She reports hav-
ing had only one sex partner. If this is true, the 
partner is HIV-positive; if it is not true, there is a 
high possibility of concurrent partners becoming 
infected, since acute HIV infection is associated 
with very high viral loads and transmission risk.39 
Her partner should be encouraged to receive HIV 
counseling and testing. If issues such as gender 
violence preclude discussion with the partner, bar-
rier contraception or abstinence are alternative 
strategies to be considered.
Dr. Gandhi: Dr. Ndung’u, would you tell us what 
happened to this patient?
Dr. Ndung’u: The patient is currently seen in 
the clinic every 6 months. At the time of her last 
visit, 1 year after the onset of her illness, her CD4+ 
T-cell count was 514 cells per cubic millimeter 
and her plasma HIV-1 RNA load was 30,644 cop-
ies per milliliter. She remains off antiretroviral 
therapy. During one visit, she reported a sore 
throat, headache, and lymphadenopathy. She is 
otherwise well.
Fina l Di agnosis
Acute HIV infection with concurrent sexually trans-
mitted infection.
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This case was presented at the Fourth Annual Workshop on Ad-
vanced Clinical Care — AIDS in Durban, South Africa, September 
30–October 1, 2010. The workshop was sponsored by the Harvard 
University Center for AIDS Research, McCord Hospital (Durban), 
the University of KwaZulu-Natal, the South African HIV Clinicians 
Society, and the Department of Health of KwaZulu-Natal.
No potential conflict of interest relevant to this article was re-
ported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Vivek Naranbhai for assistance with the preparation 
of slides and presentation of the epidemiology section at the con-
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Lantern Slides Updated: Complete PowerPoint Slide Sets from the Clinicopathological Conferences
Any reader of the Journal who uses the Case Records of the Massachusetts General Hospital as a teaching exercise or reference 
material is now eligible to receive a complete set of PowerPoint slides, including digital images, with identifying legends, 
shown at the live Clinicopathological Conference (CPC) that is the basis of the Case Record. This slide set contains all of the 
images from the CPC, not only those published in the Journal. Radiographic, neurologic, and cardiac studies, gross specimens, 
and photomicrographs, as well as unpublished text slides, tables, and diagrams, are included. Every year 40 sets are produced, 
averaging 50-60 slides per set. Each set is supplied on a compact disc and is mailed to coincide with the publication of the 
Case Record.
The cost of an annual subscription is $600, or individual sets may be purchased for $50 each. Application forms for the current 
subscription year, which began in January, may be obtained from the Lantern Slides Service, Department of Pathology, 
Massachusetts General Hospital, Boston, MA 02114 (telephone 617-726-2974) or e-mail Pathphotoslides@partners.org.
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